GLPwatch

A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People

NCT05227196 · Completed

Last updated 2026-05-28

This study is testing whether two different forms of the oral diabetes medication semaglutide are absorbed similarly in healthy people and those with type 2 diabetes.

Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 546 people
Who can join Ages 18–64 · all sexes Healthy volunteers accepted.
Timeline Started 2022-02 · est. completion 2023-08
Where 3 sites · Canada, United States

What this study is testing ClinicalTrials.gov NCT05227196 ↗

Description as written by the study sponsor.

The aim of this study is to investigate the amount of the active ingredient and helping agent in the blood in two different tablet versions of Semaglutide. The study will consist of 3 groups and the treatment the participants will get is dependent on the group the participants will be enrolled in. The participants in group 1 will receive treatment for 22 weeks, group 2 for 21 weeks and group 3 for 20 weeks. The study will last up to 29 to 31 weeks for each participant. This includes a screening period (up to 4 weeks), a dose escalation period (up to 2 weeks), a treatment period (20 weeks) and a follow-up period (5 weeks after the last dose).

Treatments tested

Main thing measuredAUC0-24h,semaglutide,SS Area under the semaglutide plasma concentration-time curve during a dosing interval at steady state (SS)
SponsorNovo Nordisk A/S
Conditions studiedHealthy Volunteers, Type 2 Diabetes
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05227196 ↗